Long‐term use of ciclosporin in a real‐world setting

1 Dye C, Scheele S, Dolin P et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999; 282:677–86. 2 Antonucci G, Girardi E, Raviglione M, Ippolito G. Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA 1995; 274:143–8. 3 Flynn J, Goldstein M, Chan J et al. Tumour necrosis factor-a is required in the protective immune response against mycobacterium tuberculosis in mice. Immunity 1995; 2:561–72. 4 Barry S, Lipman M, Bannister B et al. Purified protein derivative-activated type 1 cytokine producing CD4 T lymphocytes in the lung: a characteristic feature of active pulmonary and nonpulmonary tuberculosis. J Infect Dis 2003; 187:243–50. 5 G omez-Reino J, Carmona L, Valverde V et al. Treatment of tuberculosis with tumour necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multi-centre active surveillance report. Arthritis Rheum 2003; 48:2122–7. 6 Perlmutter A, Mittel A, Menter A. Tuberculosis and tumour necrosis factor-a inhibitor therapy: a report of three cases in patients with psoriasis: comprehensive screening and therapeutic guidelines for clinicians. Br J Dermatol 2009; 160:8–15. 7 Gisondi P, Cazzaniga S, Chimenti S et al. Latent tuberculosis infection in patients with chronic plaque psoriasis: evidence from the Italian Psocare Registry. Br J Dermatol 2015; 172:1613–20. 8 Den Boon S, Van Lill S, Borgdorff M et al. Association between smoking and tuberculosis infection: a population survey in a high incidence tuberculosis area. Thorax 2005; 60:555–7. 9 Wang L, Turner M, Elwood R et al. A meta-analysis of the effect of Bacille Calmette Gu erin vaccination on tuberculin skin test measurements. Thorax 2002; 57:804–9.